Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
Clinical trial NCT03164772 · COMPLETED
Trial details
- NCT number
- NCT03164772
- Sponsor
- Ludwig Institute for Cancer Research
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-20
- Primary completion
- 2021-10-29
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.